Ascelia Pharma AB

Stocks

Market Closed - Nasdaq Stockholm 12:00:00 2026-10-23 EDT			5-day change	1st Jan Change
0.5200 ^SEK	+1.96%		-7.47%	-83.83%

10-12	Redeye sees potential path forward for Ascelia after FDA update	FW
10-12	Ascelia Pharma AB - Special Call

Published on 10/12/2026 at 03:36 am EDT - Modified on 10/12/2026 at 04:35 am EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Welcome to Ascelia Pharma Investor Update October 2026. [Operator Instructions]

Now I will hand the conference over to the

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

10-12	Redeye sees potential path forward for Ascelia after FDA update	FW
10-12	Ascelia Pharma AB - Special Call
10-12	DNB Carnegie maintains 50 percent probability of approval for Ascelia Pharma's Orviglance	FW
10-12	US FDA Requests Additional Clinical Evidence for Ascelia Pharma's Orviglance Application	MT
10-12	Ascelia Pharma: FDA requires additional clinical evidence for Orviglance	FW
10-11	Ascelia Pharma AB Provides Orviglance Update Following Fda Type A Meeting	CI
09-24	Ascelia study on Orviglance published in scientific journal	FW
09-10	Ascelia Pharma has held FDA meeting on Orviglance	FW
08-24	DNB Carnegie lowers bottom end of valuation range for Ascelia Pharma	FW
08-20	Ascelia Pharma AB, H1 2026 Earnings Call, Aug 20, 2026
08-20	Ascelia Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Ascelia Pharma narrowed its loss in the second quarter	FW
08-20	Calendar Thursday, August 20	FW
08-17	Ascelia Pharma to Meet With US FDA on Orviglance Drug Application	MT
08-17	Ascelia Pharma to hold FDA meeting on Orviglance on September 9	FW